Total neoadjuvant therapy versus standard neoadjuvant treatment strategies for the management of locally advanced rectal cancer: network meta-analysis of randomized clinical trials.

BACKGROUND This study compared the advantages and disadvantages of total neoadjuvant therapy (TNT) strategies for patients with locally advanced rectal cancer, compared with the more traditional multimodal neoadjuvant management strategies of long-course chemoradiotherapy (LCRT) or short-course radiotherapy (SCRT). METHODS A systematic review and network meta-analysis of exclusively RCTs was undertaken, comparing survival, recurrence, pathological, radiological, and oncological outcomes. The last date of the search was 14 December 2022. RESULTS In total, 15 RCTs involving 4602 patients with locally advanced rectal cancer, conducted between 2004 and 2022, were included. TNT improved overall survival compared with LCRT (HR 0.73, 95 per cent credible interval 0.60 to 0.92) and SCRT (HR 0.67, 0.47 to 0.95). TNT also improved rates of distant metastasis compared with LCRT (HR 0.81, 0.69 to 0.97). Reduced overall recurrence was observed for TNT compared with LCRT (HR 0.87, 0.76 to 0.99). TNT showed an improved pCR compared with both LCRT (risk ratio (RR) 1.60, 1.36 to 1.90) and SCRT (RR 11.32, 5.00 to 30.73). TNT also showed an improvement in cCR compared with LCRT (RR 1.68, 1.08 to 2.64). There was no difference between treatments in disease-free survival, local recurrence, R0 resection, treatment toxicity or treatment compliance. CONCLUSION This study provides further evidence that TNT has improved survival and recurrence benefits compared with current standards of care, and may increase the number of patients suitable for organ preservation, without negatively influencing treatment toxicity or compliance.

[1]  E. Holliday,et al.  Patient-Reported Bowel Function and Quality of Life Following Short and Long Course Radiotherapy for Locally Advanced Rectal Cancer , 2022, International Journal of Radiation Oncology*Biology*Physics.

[2]  P. Cataldo,et al.  Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Chen Hu,et al.  Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Friede,et al.  Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. , 2021, JAMA oncology.

[5]  R. Garfinkle,et al.  Low Anterior Resection Syndrome: Predisposing Factors and Treatment. , 2021, Surgical oncology.

[6]  T. Conroy,et al.  Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[7]  R. Gupta,et al.  Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial. , 2021, The British journal of surgery.

[8]  J. Coffey,et al.  Urogenital function following robotic and laparoscopic rectal cancer surgery: meta-analysis. , 2021, The British journal of surgery.

[9]  S. Hoffe,et al.  Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation , 2021, CA: a cancer journal for clinicians.

[10]  E. Brecelj,et al.  Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure , 2021, World journal of gastrointestinal oncology.

[11]  E. Cotte,et al.  Impact of early biochemical diagnosis of anastomotic leakage after rectal cancer surgery: long-term results from GRECCAR 5 trial. , 2021, The British journal of surgery.

[12]  H. Prenen,et al.  Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges. , 2021, Clinical colorectal cancer.

[13]  C. V. D. van de Velde,et al.  Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. , 2020, The Lancet. Oncology.

[14]  H. Putter,et al.  Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[15]  J. Meyerhardt,et al.  NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  A. de Buck van Overstraeten,et al.  Nonoperative Management Versus Radical Surgery of Rectal Cancer after Neoadjuvant Therapy-Induced Clinical Complete Response: A Markov Decision Analysis. , 2020, Diseases of the colon and rectum.

[17]  D. Winter,et al.  Author response to: Should a minimum 8‐week interval between preoperative radiotherapy and surgery become the standard of care? No, it shouldn't , 2020, The British journal of surgery.

[18]  Julian P T Higgins,et al.  CINeMA: An approach for assessing confidence in the results of a network meta-analysis , 2020, PLoS medicine.

[19]  I. Nagtegaal,et al.  How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. , 2020, Cancer treatment reviews.

[20]  L. Moretti,et al.  Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines. , 2019, Cancer treatment reviews.

[21]  Audrey Béliveau,et al.  BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses , 2019, BMC Medical Research Methodology.

[22]  Joon-Oh Park,et al.  Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. , 2019, Journal of Clinical Oncology.

[23]  P. Neary,et al.  Meta‐analysis of the effect of extending the interval after long‐course chemoradiotherapy before surgery in locally advanced rectal cancer , 2019, The British journal of surgery.

[24]  J. Kładny,et al.  Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  D. Winter,et al.  Minimally invasive approaches to the management of anastomotic leakage following restorative rectal cancer resection , 2019, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[26]  Y. Lim,et al.  Adjuvant chemotherapy in rectal cancer patients who achieved a pathological complete response after preoperative chemoradiotherapy: a systematic review and meta-analysis , 2019, Scientific Reports.

[27]  T. Friede,et al.  Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Gama-Rodrigues,et al.  Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think! , 2019, Diseases of the colon and rectum.

[29]  J. Brierley,et al.  Patient and Physician Preferences for Nonoperative Management for Low Rectal Cancer: Is It a Reasonable Treatment Option? , 2018, Diseases of the colon and rectum.

[30]  J. Parsons,et al.  Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer , 2018, The British journal of surgery.

[31]  N. Hyman,et al.  Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial , 2018, Diseases of the colon and rectum.

[32]  E. Consten,et al.  Effect of Neoadjuvant Therapy and Rectal Surgery on Health‐related Quality of Life in Patients With Rectal Cancer During the First 2 Years After Diagnosis , 2018, Clinical colorectal cancer.

[33]  B. Karabulut,et al.  Randomized clinical trial of short or long interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer , 2018, The British journal of surgery.

[34]  J. Joo,et al.  A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. , 2018, International journal of radiation oncology, biology, physics.

[35]  G. Beets,et al.  Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study , 2018, The Lancet.

[36]  M. Thomas,et al.  Prospective randomized trial of neoadjuvant chemotherapy during the ‘wait period’ following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial , 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[37]  Zhenchao Tang,et al.  Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer , 2017, Clinical Cancer Research.

[38]  H. Johansson,et al.  Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. , 2017, The Lancet. Oncology.

[39]  D. Pavalkis,et al.  Preoperative conventional chemoradiotherapy versus short-course radiotherapy with delayed surgery for rectal cancer: results of a randomized controlled trial , 2016, BMC Cancer.

[40]  E. Cotte,et al.  Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Dybko,et al.  Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  S. Laurberg,et al.  Predicting the Risk of Bowel-Related Quality-of-Life Impairment After Restorative Resection for Rectal Cancer: A Multicenter Cross-Sectional Study , 2016, Diseases of the colon and rectum.

[43]  Nicky J Welton,et al.  Automated generation of node‐splitting models for assessment of inconsistency in network meta‐analysis , 2015, Research synthesis methods.

[44]  D. Moher,et al.  The PRISMA Extension Statement , 2015, Annals of Internal Medicine.

[45]  David D. Smith,et al.  Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. , 2015, The Lancet. Oncology.

[46]  T. Hothorn,et al.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[47]  C. Montagut,et al.  Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  H. Putter,et al.  Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. , 2015, The Lancet. Oncology.

[49]  T. Beißbarth,et al.  Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  K. Goodman,et al.  Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[51]  L. Collette,et al.  Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. , 2014, The Lancet. Oncology.

[52]  Huseyin Naci,et al.  Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers , 2013, BMC Medicine.

[53]  T. Saclarides,et al.  Hospital Readmission for Fluid and Electrolyte Abnormalities Following Ileostomy Construction: Preventable or Unpredictable? , 2013, Journal of Gastrointestinal Surgery.

[54]  D. Goldstein,et al.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  R. Glynne-Jones,et al.  Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Kristian Thorlund,et al.  How to use an article reporting a multiple treatment comparison meta-analysis. , 2012, JAMA.

[57]  Torsten Hothorn,et al.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. , 2012, The Lancet. Oncology.

[58]  H. Heneghan,et al.  Systematic review and meta‐analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer , 2012, The British journal of surgery.

[59]  D. Franchimont,et al.  Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  W. Hohenberger,et al.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  D. Pavalkis,et al.  Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short‐course radiotherapy or long‐term chemoradiotherapy, both with delayed surgery , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[62]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[63]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[64]  L. Påhlman,et al.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  L. Påhlman,et al.  Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer , 2010, The British journal of surgery.

[66]  S. Polo,et al.  Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer d , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  V. Fazio,et al.  Predictive Factors of Pathologic Complete Response After Neoadjuvant Chemoradiation for Rectal Cancer , 2009, Annals of surgery.

[68]  Lars Påhlman,et al.  Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Yuan Ji,et al.  Bayesian models based on test statistics for multiple hypothesis testing problems , 2008, Bioinform..

[70]  K. Bujko,et al.  Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer , 2006, The British journal of surgery.

[71]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[72]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[73]  J. Kładny,et al.  Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[74]  H. Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. , 2001, The New England journal of medicine.

[75]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[76]  OUP accepted manuscript , 2021, British Journal of Surgery.

[77]  T. Žvirblis,et al.  Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II-III resectable rectal cancer: 5-Year survival data of a randomized controlled trial. , 2017, Medicina.

[78]  J. Niland,et al.  Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.